Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-25-001043
Filing Date
2025-02-14
Accepted
2025-02-14 16:12:14
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 9457
  Complete submission text file 0000902664-25-001043.txt   11129
Mailing Address 350 MADISON AVENUE 20TH FLOOR NEW YORK NY 10017
Business Address 350 MADISON AVENUE 20TH FLOOR NEW YORK NY 10017 2127166576
ALKEON CAPITAL MANAGEMENT LLC (Filed by) CIK: 0001230239 (see all company filings)

EIN.: 134200093 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Subject) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-91484 | Film No.: 25628760
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)